Biosimilar Development for Rheumatic Disease

In this downloadable slideset, Stanley B. Cohen, MD, reviews the regulatory pathway and development of biosimilars.
Stanley B. Cohen, MD
Jonathan Kay, MD
Kenneth G. Saag, MD, MSc
Format: Microsoft PowerPoint (.ppt)
File Size: 622 KB
Released: November 21, 2017

Acknowledgements

Jointly provided by Postgraduate Institute for Medicine and Clinical Care Options, LLC.
PIM Logo

Postgraduate Institute for Medicine
304 Inverness Way South, Suite 100
Englewood, CO 80112

Allison Hughes, CCMEP, Program Manager
(303) 799-1930
(303) 858-8842 (Fax)
ahughes@pimed.com
www.pimed.com

Supported by independent educational grants from
Boehringer Ingelheim Pharmaceuticals, Inc.
Sandoz Inc., a Novartis Division

Related Content

Phase I/III study of CT-P13 SC shows noninferior efficacy, similar safety vs IV in RA patients. Report from EULAR 2019 by CCO.

Released: June 21, 2019

New data from the SEMIRA study of prednisone withdrawal in patients with RA from EULAR 2019 as reported by Clinical Care Options Oncology

Released: June 19, 2019

Primary outcome analysis from the FINCH1 study of JAK-1 inhibitor filgotinib in patients with RA from EULAR 2019 as reported by Clinical Care Options.

Released: June 18, 2019

Tofacitinib monotherapy: ORAL Shift shows MTX withdrawal does not worsen RA in patients receiving tofacitinib plus MTX from EULAR 2019 reported by CCO.

Released: June 18, 2019

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.

Continue

More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?